Yu Tian, Rajendran Vijayalakshmi, Griffith May, Forrester John V, Kuffová Lucia
Tian Yu, Vijayalakshmi Rajendran, John V Forrester, Lucia Kuffová, Section of Immunity, Infection and Inflammation, Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Scotland AB25 2ZD, United Kingdom.
World J Transplant. 2016 Mar 24;6(1):10-27. doi: 10.5500/wjt.v6.i1.10.
Corneal transplantation is the most common surgical procedure amongst solid organ transplants with a high survival rate of 86% at 1-year post-grafting. This high success rate has been attributed to the immune privilege of the eye. However, mechanisms originally thought to promote immune privilege, such as the lack of antigen presenting cells and vessels in the cornea, are challenged by recent studies. Nevertheless, the immunological and physiological features of the cornea promoting a relatively weak alloimmune response is likely responsible for the high survival rate in "low-risk" settings. Furthermore, although corneal graft survival in "low-risk" recipients is favourable, the prognosis in "high-risk" recipients for corneal graft is poor. In "high-risk" grafts, the process of indirect allorecognition is accelerated by the enhanced innate and adaptive immune responses due to pre-existing inflammation and neovascularization of the host bed. This leads to the irreversible rejection of the allograft and ultimately graft failure. Many therapeutic measures are being tested in pre-clinical and clinical studies to counter the immunological challenge of "high-risk" recipients. Despite the prevailing dogma, recent data suggest that tissue matching together with use of systemic immunosuppression may increase the likelihood of graft acceptance in "high-risk" recipients. However, immunosuppressive drugs are accompanied with intolerance/side effects and toxicity, and therefore, novel cell-based therapies are in development which target host immune cells and restore immune homeostasis without significant side effect of treatment. In addition, developments in regenerative medicine may be able to solve both important short comings of allotransplantation: (1) graft rejection and ultimate graft failure; and (2) the lack of suitable donor corneas. The advances in technology and research indicate that wider therapeutic choices for patients may be available to address the worldwide problem of corneal blindness in both "low-risk" and "high-risk" hosts.
角膜移植是实体器官移植中最常见的外科手术,移植后1年的存活率高达86%。这一高成功率归因于眼睛的免疫赦免特性。然而,最初认为促进免疫赦免的机制,如角膜中缺乏抗原呈递细胞和血管,受到了近期研究的挑战。尽管如此,角膜促进相对较弱的同种异体免疫反应的免疫和生理特征可能是“低风险”情况下高存活率的原因。此外,虽然“低风险”受者的角膜移植存活率良好,但“高风险”受者的角膜移植预后较差。在“高风险”移植中,由于宿主床先前存在的炎症和新生血管形成,先天和适应性免疫反应增强,间接同种异体识别过程加速。这导致同种异体移植物不可逆转的排斥,最终导致移植失败。许多治疗措施正在临床前和临床研究中进行测试,以应对“高风险”受者的免疫挑战。尽管存在普遍的教条,但最近的数据表明,组织配型与全身免疫抑制的使用可能会增加“高风险”受者接受移植物的可能性。然而,免疫抑制药物伴有不耐受/副作用和毒性,因此,正在开发针对宿主免疫细胞并恢复免疫稳态而无明显治疗副作用的新型细胞疗法。此外,再生医学的发展可能能够解决同种异体移植的两个重要缺点:(1)移植物排斥和最终移植失败;(2)缺乏合适的供体角膜。技术和研究的进展表明,对于患者可能有更广泛的治疗选择,以解决“低风险”和“高风险”宿主中全球范围内的角膜盲问题。